Published in Lancet on January 01, 1983
Epidemiology of scleroderma. Ann Rheum Dis (1991) 1.13
Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis (1994) 1.05
Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis. PLoS One (2012) 0.91
Epidemiology of organic solvents and connective tissue disease. Arthritis Res (1999) 0.84
Clinical aspects of systemic sclerosis (scleroderma). Ann Rheum Dis (1991) 0.83
Major histocompatibility complex class II genes and systemic sclerosis. Ann Rheum Dis (1991) 0.82
Regressive systemic sclerosis. Ann Rheum Dis (1986) 0.75
Source of infection in Hickman catheters. J Clin Pathol (1986) 0.75
Chronic juvenile toxic epidemic syndrome. Ann Rheum Dis (1985) 0.75
Type 1 diabetes mellitus, celiac disease, systemic lupus erythematosus and systemic scleroderma in a 15-year-old girl. Rheumatol Int (2009) 0.75
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 6.33
Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet (1996) 4.33
The National Survey of Stroke. Clinical findings. Stroke (1981) 3.45
Identity of the proliferating cell nuclear antigen and cyclin. Nature (1984) 3.44
A systematic review of discharge coding accuracy. J Public Health Med (2001) 3.36
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
The Projection of the Medial Geniculate Body to the Cerebral Cortex in the Macaque Monkey. J Anat (1937) 2.80
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature (1983) 2.71
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet (1980) 2.63
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis (1995) 2.59
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A (1999) 2.45
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol (1982) 2.29
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet (1981) 2.23
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Preliminary report: dramatic rise in renal allograft failure rate. Lancet (1990) 2.09
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med (1990) 2.03
Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum (1989) 2.02
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Issues in data monitoring and interim analysis of trials. Health Technol Assess (2005) 1.96
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J Exp Med (1979) 1.88
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol (2000) 1.73
Progestins and breast cancer: an epidemiologic review. Fertil Steril (1992) 1.71
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) (1984) 1.68
Diversity of autoantibodies in primary biliary cirrhosis and chronic active hepatitis. Clin Exp Immunol (1984) 1.67
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
Identification of antibodies to acidic antigens by counterimmunoelectrophoresis. Ann Rheum Dis (1982) 1.64
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology (2001) 1.60
Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 1.59
Hydrallazine-induced cutaneous vasculitis. Br Med J (1980) 1.59
Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health (1982) 1.57
Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology (1985) 1.57
Use of an automated device for alternative site blood glucose monitoring. Diabetes Care (2001) 1.57
Production of beta 2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev (1974) 1.57
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med (1984) 1.54
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
Anticentromere antibody in primary biliary cirrhosis. Ann Rheum Dis (1982) 1.53
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut (2000) 1.52
Labeled staphylococcal protein A as an immunological probe in the analysis of cell surface markers. Scand J Immunol (1974) 1.52
Cellular protein and RNA antigens in autoimmune disease. Mol Biol Med (1984) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
A radioimmunoassay of cellular surface antigens on living cells using iodinated soluble protein A from Staphylococcus aureus. J Immunol Methods (1975) 1.50
Molecular origins and evolution of immunoglobulin heavy-chain genes of jawed vertebrates. Immunol Today (1997) 1.50
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Genes encoding the beta-chains of HLA-DR7 and HLA-DQw2 define major susceptibility determinants for idiopathic nephrotic syndrome. Clin Sci (Lond) (1990) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Mannose-binding lectin promoter and structural gene variants in sarcoidosis. Eur J Clin Invest (2000) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
The March 2002 update of the electronic version of ICPC-2. A step forward to the use of ICD-10 as a nomenclature and a terminology for ICPC-2. Fam Pract (2002) 1.44
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol (1997) 1.42
Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut (2003) 1.42
The immune response to allogeneic rat platelets; Ag-B antigens in matrix form lacking Ia. Eur J Immunol (1977) 1.42
Glycosylated haemoglobin in rheumatoid arthritis. Ann Rheum Dis (1982) 1.42
A new colon carcinoma cell line (LIM1863) that grows as organoids with spontaneous differentiation into crypt-like structures in vitro. Cancer Res (1987) 1.42
Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol (2000) 1.42
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41